Anti-HBV effect of TAT- HBV targeted ribonuclease

Jin Ding, Jun Liu, Cai-fang Xue, Wei-dong Gong, Ying-hui Li, Ya Zhao

Abstract

AIM: To prepare and purify TAT-HBV targeted ribonuclease fusion protein, evaluate its transduction activity and investigate its effect on HBV replication in 2.2.15 cells.

METHODS: The prokaryotic expression vector pTAT containing TR gene was used in transforming E.coli BL21 (DE3) LysS and TR was expressed with the induction of IPTG. The TAT-TR fusion protein was purified using Ni-NTA-agrose and PD-10 desalting columns, and analyzed by SDS-PAGE. Transduction efficiency of TAT-TR was detected with solid-phase radioimmunoassay (spRIA). MTT assay was used in the supernatant of the 2.2.15 cells was determined via immunofluorescence assay and the concentration of HBeAg in the supernatant of the 2.2.15 cells was determined via solid-phase radioimmunoassay (spRIA). MTT assay was used to detect the cytopathicity of TAT-TR.

RESULTS: The SDS-PAGE showed that the TAT-TR fusion protein was purified successfully, and the purity of TAT-TR was 90%. The visualization of TAT-TR by immunofluorescence assay indicated its high efficiency in transducing 2.2.15 cells. RIA result suggests that TAT-TR could inhibit the replication of HBV effectively, it didn’t affect cell growth and had no cytotoxicity.

CONCLUSION: TAT-TR possesses a significant anti-HBV activity and the preparation of TAT-TR fusion protein has laid the foundation for the use of TR in the therapeutic trial of HBV infection.

Jin Ding, Jun Liu, Cai-fang Xue, Wei-dong Gong, Ying-hui Li, Ya Zhao. Anti-HBV effect of TAT- HBV targeted ribonuclease. World J Gastroenterol 2003; 9(7): 1525-1528

http://www.wjgnet.com/1007-9327/9/1525.asp

INTRODUCTION

The introduction of proteins into mammalian cells has been achieved by transfection of expression vectors, microinjection, or infectious virus, etc. Although these approaches have been somewhat successful, the classical manipulation methods are not easily regulated and can be laborious. One approach to resolve these problems is the use of PTD-mediated protein transduction[1-2]. Linked covalently to proteins, peptides, nucleic acids, or as in-frame fusions with full-length proteins, PTD would let them enter any cell type in a receptor and transporter independent fashion[3]. HIV-TAT is a member of protein transduction domains and appears to possess high level of protein-transduction efficiency[4,5]. TAT fusion proteins were shown to transduce into all cells and tissues present in mice[6], including those present across the blood-brain barrier[7,8]. And many, if not most, proteins may be transduced into cells by using this technology. Therefore, TAT PTD may let us address new questions in preclinical research work and even help in the treatment of human disease.

Hepatitis B is a major world-wide health problem[9-13]. Chronic infection is associated with high risk of liver cirrhosis and primary liver carcinoma[14-22]. Currently available therapies are of limited efficiency[23-35]. HBV targeted ribonuclease (TR) gene, a fusion gene of HBVc and hEDN, was constructed by Liu et al[26], according to the theory of capsid-targeted viral inactivation (CTVI) which is a promising strategy in anti-virus research. HBVc was used as the target molecule, which was the structure protein of HBV and was indispensable during the packaging of HBV particle. The effector molecule was hEDN, a kind of human ribonuclease that can degrade pgRNA of HBV. Transfection of 2.2.15 cells with the eukaryotic expression vector bearing TR gene suggested that TR inhibited the replication of HBV significantly[27]. Therefore, linking HIV-TAT to TR would provide us a more efficient approach to deliver TR into hepatocytes, and greatly help us to utilize TR in the treatment of HBV infection. Reported here are the purification of TAT-TR fusion protein, the identification of its transduction and the anti-HBV effect on the 2.2.15 cells. To confirm its anti-HBV mechanism, we also prepared and purified TAT-TRmut, TAT-hEDN and TAT-HBVc proteins for use as negative controls.

MATERIALS AND METHODS

Materials

Ni-NTA-agrose was purchased from Qiagen Company. PD-10 desalting columns were purchased from Amersham Pharmacia Biotech. Anti-his mAb was from Santa Cruz Biotechnology Institute. 2.2.15 cells was a kind gift of Prof. Cheng, 302 Hospital of Chinese PLA. hEDN was purified by Li et al[36], pTAT-HA/TR, TAT-HA/TRmut, pTAT-HA/hEDN and pTAT-HA/HBVc were all prepared in our Lab[38]. PET-30a/TR, PET-30a/TRmut, PET-30a/HBVc and E.coli BL21 (DE3) LysS were maintained in our Lab.

Methods

Expression and purification of TAT fusion proteins pTAT-HA/TR, TAT-HA/TRmut, pTAT-HA/hEDN, pTAT-HA/HBVc and pTAT-HA were employed to transform E.coli BL21 (DE3) LysS by using CaCl₂ perforation. The transformants were separately cultured in 3 mL TB amp (100 µg/L) at 37 ℃ overnight. 100 µL culture was inoculated into 10 mL fresh TB amp, and incubated for up to 4 hours at 37 ℃. Then IPTG was added to each tube to a final concentration of 100 µmol/L, and the culture was incubated for an additional 4 hours. The induced cells were harvested by centrifugation, and cell lysates were analyzed by 120 g/L SDS-PAGE. The his-tagged fusion
proteins were purified by using Ni-NTA-agarose and PD-10 desalting columns according to the manufacturer’s recommendations (Qiagen and Amersham Pharmacia). The purified proteins were analyzed by 120 g/L SDS-PAGE.

**Expression and purification of proteins without TAT PTD**

PET-30a/TR, pET-30a/TRmut, and pET-30a/HBVc transformed E.coli BL21 (DE3) LysS. After the analysis of expression levels, the three proteins were purified in the same way as for TAT fusion proteins.

**Culture of 2.2.15 cells**

Cells were cultured in DMEM containing 150 mL/L fetal bovine serum at 37 °C in 50 mL/L CO2 and 100 mg/L G418.

**Identification of TAT fusion protein transduction**

2.2.15 cells (2×10^6/L) were plated into 6-well plates with coverships, and allowed to adhere for 24 hours. TAT-TR, TAT-TRmut, TAT-hEDN, TAT-HBVc, TR, TRmut, hEDN and HBVc were added into the wells, respectively, at the final concentration of 100 nmol/L. Incubated for 30 min at 37 °C, all cells were immediately washed with sterile PBS (pH8.0), fixed in 20 g/L paraformaldehyde and 1 g/L TritonX-100 diluted in PBS and put on ice for 30 min. Cells were washed three times with cold PBS. Non-specific epitopes were blocked by using 10 g/L BSA for 10 min at 42 °C. Cells were washed three times with cold PBS, and then incubated with mouse anti-His mAb (1:500) for 15 min at 42 °C. After washing three times in cold PBS, the rabbit anti-mouse IgG labeled with FITC (1:1 000) was added to each well and incubated for 10 min at 42 °C. Rinsed with PBS for 1 hour and the coverships were mounted on slides by using 500 mL/L glycerol. The cells were observed by fluorescence microscopy.

**Determination of anti-HBV effect of TAT-TR**

2.2.15 cells were plated at the density of 2×10^6/L into 12-well plates. TAT-TR, TAT-TRmut, TAT-hEDN and TAT-HBVc were added into the wells, respectively, at the final concentration of 100 nmol/L. 20 μL DMEM was added into wells as mock group. Four parallels were set up for each group. 24 hours later, HBVeAg in the supernatant was determined by using spRIA kit as described by the manufacturer.

**MTT assay**

2.2.15 cells were plated at the density of 2×10^5/L into 96-well plates. After 24 hours, TAT-TR, TAT-TRmut, TAT-hEDN, TAT-HBVc were added into (A), (B), (C), (D) groups at the final concentration of 100 nmol/L. 20 μL DMEM was added into well (E). 72 hours later, the morphology of cells was observed through inverted microscopy and MTT was applied in each well at the final concentration of 5 g/L. After another 4 hours’ culturing, 150 μL DMSO was added into all wells and the light absorbance at A_{490} was detected.

**Statistical analysis**

All data obtained were processed by SPSS software. P<0.05 was considered statistically significant.

**RESULTS**

**Expression and purification of TAT fusion proteins**

In order to obtain the fusion proteins, pTAT-HA/TR, pTAT-HA/Trmut, pTAT-HA/hEDN and pTAT-HA/HBVc were used to transform E.coli BL21 (DE3) LysS and expressed with the induction of IPTG. The same strain transformed by pTAT-HA was used as negative control. The expression levels were determined by 120 g/L SDS-PAGE. Four predicted new bands could be detected in the lysates of TAT fusion transfectants, but not in the control. Then the proteins were purified by using Ni-NTA affinity columns and PD-10 desalting columns (Figure 1). The degrees of purity of the fusion proteins were 90 %, 88 %, 80 % and 85 % respectively.
transduction provides several advantages over DNA transfection, the current standard method of intracellular protein expression. Importantly, all eukaryotic cell types tested to date are susceptible to transduction, even osteoclasts, primary cells and peripheral-blood mononuclear cells, which are impervious to DNA transfection and retroviral infection, can be effectively transduced\(^\text{[14, 15]}\). Additionally, as transduction occurs so rapidly (15 min rather than 12 h in serum-free media for transfection), issues of timing can be addressed. The exact intracellular concentration can also be controlled precisely just by varying the amount added to the culture medium. Furthermore, every cell in the population appears to contain a near-identical intracellular protein level\(^\text{[15]}\). Another dominant advantage of the system allows denatured fusion protein be directly applied without the laborious renature course, and thus it also provides much convenience for protein purification. Once transduced inside the cells, the denatured proteins can be correctly refolded by chaperones\(^\text{[45]}\), and are capable of binding their cognate intracellular targets and performing biochemical functions.

To explore the feasibility of using PTD in the anti-HBV research work and provide an alternative strategy for treatment of hepatitis B in this study, we prepared and purified the TAT-TR fusion protein, and also other control proteins. Transduction of TAT-fusion proteins was detected by immunofluorescence assay. Strong fluorescence appeared in the cytoplasm of the cells applied with four TAT fusion proteins, but not in the control groups. These results showed the high transduction efficiency of TAT fusion proteins. We also investigated TAT-TR’s anti-HBV activity by radioimmunoassay and got an exciting result. As compared with the mock group, concentration of HBeAg in TAT-TR group decreased by 60.3 %, which indicated that the purified TAT-TR possessed a potent anti-HBV activity. There was no significant difference between any other group and the mock group, suggesting HBVc or hEDN alone had no effect on HBV replication, and TRmut, a fusion molecule of HBVc with an inactivated mutant hEDN, also had no inhibitory effect. These further confirmed the anti-HBV mechanism of the HBV targeted ribonuclease. While TR was transduced into 2.2.15 cells, it could be packaged into the HBV core particles by HBVc, and then hEDN, as a ribonuclease, could degrade the pgRNA packed in the core particles, thus inhibiting the replication of HBV. We performed MTT assay to reveal whether the TAT fusion proteins were harmful to 2.2.15 cells, and the results indicate that they did not affect the growth of 2.2.15 cells and the purified TAT-TR may be applied in vivo. Therefore, we conclude that the TAT-HBV targeted ribonuclease fusion protein obtained in this study has laid the foundation for using TR in the therapy of HBV infection.
REFERENCES

1. Becker-Hapak M, McAllister SS, Dowdy SF. TAT-mediated protein transduction into mammalian cells. Methods 2001; 24: 247-256

2. Schwarze SR, Dowdy SF. In vivo protein transduction: intracellular delivery of bioactively active proteins, compounds and DNA. Trends Pharmacol Sci 2000; 21: 45-48

3. Schwarze SR, Hruska KA, Dowdy SF. Protein transduction: unrestricted delivery into all cells? Trends Cell Biol 2000; 10: 290-295

4. Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997; 272: 16010-16017

5. Xie Q, Guo Q, Zhou XQ, Gu RY. Effect of adenine arabinoside monophosphate coupled to lactosaminated human serum albumin on duck hepatitis B virus. Shijie Huan Xiu Xibao 1999; 7: 125-126

6. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999; 285: 1569-1572

7. Nagahara H, Vocero-Akbani AM, Snyder EL, Ho A, Latham DG, Lissy NA, Becker-Hapak M, Ezhevsky SA, Dowdy SF. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27kip1 induces cell migration. Nat Med 1998; 4: 1449-1452

8. Chellai MA, Soga N, Swanson S, McAllister S, Alvarez U, Wang D, Dowdy SF, Hruska KA. Rho-A is critical for osteoclast podosome organization, motility and bone resorption. Biol Chem 2000; 275: 11993-12002

9. Shi H, Wang FS. Host factors in chronicity of hepatitis B virus infection and their significances in clinic. Shijie Huan Xiu Xibao 2001; 9: 65-69

10. Befeler AS, Dí Bisciglie AM, Hébert P. TAT-p27kip1 induces cell migration. J Biol Chem 2000; 275: 11993-12002

11. Lau GK. Use of immunomodulatory therapy (other than interferon) for the treatment of chronic hepatitis B virus infection. J Gastroenterol Hepatol 2000; 15(Suppl): E46-52

12. Ren G. Interferon monotherapy in chronic hepatitis B. J Gastroenterol Hepatol 2000; 15(Suppl): E34-40

13. Torresi J, Locarnini S. Antiviral chemotherapy for the treatment of hepatitis B virus infections. Gastroenterology 2000; 118(Suppl): S203-103

14. Schiff ER, Lamivudine for hepatitis B in clinical practice. J Med Virol 2000; 61: 386-391

15. Jarvis B, Faulds D, Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs 1999; 58: 101-141

16. Malik AH, Lee WM. Chronic hepatitis B virus infection: treatment strategies for the next millennium. Ann Intern Med 2000; 132: 723-731

17. Farrell GC. Clinical potential of emerging new agents in hepatitis B. Drugs 2000; 60: 701-710

18. Song HY, Lin JS, Liu NZ, Kong JX, Xie N, Wang NX, Jin YX, Liang KH. Anti-HBV hairpin ribozyme-mediated cleavage of target RNA in vitro. J Gastroenterol 2002; 8: 91-94

19. Li YH, Liu J, Xue CF. Construction of HBV targeted ribonuclease and its expression in 2.15 cell line. Xibao Yu Fenzi Mianyixue Zazhi 2002; 18: 217-220

20. Liu J, Li YH, Xue CF, Ding J, Gong WD, Zhao Y. HBV targeted ribonuclease can inhibit HBV replication. World J Gastroenterol 2003; 9: 295-299

21. Ding J, Liu J, Xue CF, Li YH, Gong WD. Construction and expression of prokaryotic expression vector for pTAT-HBV targeted fusion protein. Xibao Yu Fenzi Mianyixue Zazhi 2003; 19: 49-51

22. Green M, Loewenstein PM. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 1988; 55: 1179-1188

23. Frankel AD, Pabo Co. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988; 55: 1189-1193

24. Derossi D, Joliot AH, Chassaign G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 1994; 269: 10444-10450

25. Elliot G, O’Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 1997; 88: 223-233

26. Chellai MA, Soga N, Swanson S, McAllister S, Alvarez U, Wang D, Dowdy SF, Hruska KA. Rho-A is critical for osteoclast podosome organization, motility, and bone resorption. J Biol Chem 2000; 275: 11993-2002

27. Schütze-Redmeier M, Gournier H, Garcia-Pons F, Moussa M, Joliot AH, Volvich M, Prochiantz A, Lemoine FA. Introduction of exogenous antigens into the MHC class I processing and presentation pathway by Drosophila antennapedia homeodomain primes cytotoxic T cells in vivo. J Immunol 1996; 157: 650-655

28. Gottesman S, Wickner S, Maurizi MR. Protein quality control: triage by chaperones and proteases. Genes Dev 1997; 11: 815-823

Edited by Lu HM